Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice
- PMID: 18387000
- DOI: 10.1042/BJ20080557
Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice
Abstract
The LKB1 tumour suppressor phosphorylates and activates AMPK (AMP-activated protein kinase) when cellular energy levels are low, thereby suppressing growth through multiple pathways, including inhibiting the mTORC1 (mammalian target of rapamycin complex 1) kinase that is activated in the majority of human cancers. Blood glucose-lowering Type 2 diabetes drugs also induce LKB1 to activate AMPK, indicating that these compounds could be used to suppress growth of tumour cells. In the present study, we investigated the importance of the LKB1-AMPK pathway in regulating tumorigenesis in mice resulting from deficiency of the PTEN (phosphatase and tensin homologue deleted on chromosome 10) tumour suppressor, which drives cell growth through overactivation of the Akt and mTOR (mammalian target of rapamycin) kinases. We demonstrate that inhibition of AMPK resulting from a hypomorphic mutation that decreases LKB1 expression does not lead to tumorigenesis on its own, but markedly accelerates tumour development in PTEN(+/-) mice. In contrast, activating the AMPK pathway by administration of metformin, phenformin or A-769662 to PTEN(+/-) mice significantly delayed tumour onset. We demonstrate that LKB1 is required for activators of AMPK to inhibit mTORC1 signalling as well as cell growth in PTEN-deficient cells. Our findings highlight, using an animal model relevant to understanding human cancer, the vital role that the LKB1-AMPK pathway plays in suppressing tumorigenesis resulting from loss of the PTEN tumour suppressor. They also suggest that pharmacological inhibition of LKB1 and/or AMPK would be undesirable, at least for the treatment of cancers in which the mTORC1 pathway is activated. Most importantly, our results demonstrate the potential of AMPK activators, such as clinically approved metformin, as anticancer agents, which will suppress tumour development by triggering a physiological signalling pathway that potently inhibits cell growth.
Comment in
-
Cancer therapy: staying current with AMPK.Biochem J. 2008 Jun 1;412(2):e3-5. doi: 10.1042/BJ20080823. Biochem J. 2008. PMID: 18466113
Similar articles
-
Dissecting the signaling pathways that mediate cancer in PTEN and LKB1 double-knockout mice.Sci Signal. 2015 Sep 1;8(392):pe1. doi: 10.1126/scisignal.aac8321. Sci Signal. 2015. PMID: 26329580 Review.
-
AMPK/TSC2/mTOR-signaling intermediates are not necessary for LKB1-mediated nuclear retention of PTEN tumor suppressor.Neuro Oncol. 2011 Feb;13(2):184-94. doi: 10.1093/neuonc/noq163. Epub 2010 Dec 1. Neuro Oncol. 2011. PMID: 21123367 Free PMC article.
-
LKB1 and AMP-activated protein kinase control of mTOR signalling and growth.Acta Physiol (Oxf). 2009 May;196(1):65-80. doi: 10.1111/j.1748-1716.2009.01972.x. Epub 2009 Feb 19. Acta Physiol (Oxf). 2009. PMID: 19245654 Free PMC article. Review.
-
Cancer therapy: staying current with AMPK.Biochem J. 2008 Jun 1;412(2):e3-5. doi: 10.1042/BJ20080823. Biochem J. 2008. PMID: 18466113
-
Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma.Clin Cancer Res. 2008 May 1;14(9):2543-50. doi: 10.1158/1078-0432.CCR-07-0321. Clin Cancer Res. 2008. PMID: 18451215
Cited by
-
Viability Profiles of Normal and Cancer Bladder Cells With Metformin, Nitrate and Adenosine Monophosphate-Activated Protein Kinase Inhibitor.World J Oncol. 2024 Feb;15(1):38-44. doi: 10.14740/wjon1590. Epub 2023 Jul 12. World J Oncol. 2024. PMID: 38274718 Free PMC article.
-
The development and benefits of metformin in various diseases.Front Med. 2023 Jun;17(3):388-431. doi: 10.1007/s11684-023-0998-6. Epub 2023 Jul 4. Front Med. 2023. PMID: 37402952 Review.
-
Acetyl-CoA metabolism in cancer.Nat Rev Cancer. 2023 Mar;23(3):156-172. doi: 10.1038/s41568-022-00543-5. Epub 2023 Jan 19. Nat Rev Cancer. 2023. PMID: 36658431 Free PMC article. Review.
-
Targeting mTORC1 Activity to Improve Efficacy of Radioligand Therapy in Cancer.Cancers (Basel). 2022 Dec 20;15(1):17. doi: 10.3390/cancers15010017. Cancers (Basel). 2022. PMID: 36612012 Free PMC article. Review.
-
Will We Unlock the Benefit of Metformin for Patients with Lung Cancer? Lessons from Current Evidence and New Hypotheses.Pharmaceuticals (Basel). 2022 Jun 24;15(7):786. doi: 10.3390/ph15070786. Pharmaceuticals (Basel). 2022. PMID: 35890085 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous